Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients (AHOCEP)

Sumitomo Pharma

Status and phase

Completed

Phase 4

Conditions

Chronic Kidney Disease

Treatments

Drug: Non arotinolol group

Drug: Arotinolol Hydrochloride

Study type

Interventional

Funder types

Industry

Identifiers

NCT01351636

DSPC-ALM-1101

Details and patient eligibility

About

The purpose of this study is to ascertain whether Arotinolol Hydrochloride reduces mortality and cardiovascular events in chronic kidney disease stage 5 patients with hypertension.

Enrollment

300 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged between 18-75 years-old;
Chronic kidney disease stage 5 with haemodialysis treatment for 2 months;
Patients with blood pressure≥140/90 mmHg after receiving 2 or 3 antihypertensive medications for 2 weeks;
Patients who receiving alfa or beta blockers will be washed out for 2 weeks;
Written informed consent

Exclusion criteria

Unstable angina, myocardial infarction, symptomatic or continuous arrhythmia, cardiosurgery in the last 2 months;
Patients who taking class I antiarrhythmic drugs;
Resting heart rate less than 60;
Patients with systolic pressure less than 90 mmHg;
Patients with chronic obstructive pulmonary disease and asthma;
Patients with cerebral infarction in the last 2 weeks;
Severe disorders of liver function;
Allergy to the arotinolol;
Patients who planning to have kidney transplantation in the near future;
Pregnancy and breast-feeding;
Malignant tumor